U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C6H6N6O2
Molecular Weight 194.1508
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of TEMOZOLOMIDE

SMILES

CN1N=NC2=C(N=CN2C1=O)C(N)=O

InChI

InChIKey=BPEGJWRSRHCHSN-UHFFFAOYSA-N
InChI=1S/C6H6N6O2/c1-11-6(14)12-2-8-3(4(7)13)5(12)9-10-11/h2H,1H3,(H2,7,13)

HIDE SMILES / InChI

Molecular Formula C6H6N6O2
Molecular Weight 194.1508
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment: description was created based on several sources, including https://www.google.com/patents/WO2012027693A3 | https://www.ncbi.nlm.nih.gov/pubmed/24994771

NEO 212 is novel DNA alkylating agent exhibiting superior activity against breast cancer cells in vitro and intracranial triple-negative tumor growth in vivo. NEO212 is a conjugate of temozolomide (TMZ,) with the natural product perillyl alcohol (POH). NEO 212 causes DNA damage and cell death much more efficiently than TMZ because linkage with POH increased it's biological half-life and thus provided greater opportunity for placement of cytotoxic DNA lesions.

CNS Activity

Curator's Comment: TMZ (TEMOZOLOMIDE) is 100% bioavailable when taken orally and, because of its small size and lipophilic properties, it is able to cross the blood-brain barrier. Concentrations in the central nervous system are approximately 30% of plasma concentrations. Once it has entered the central nervous system, TMZ can be spontaneously converted to the active metabolite. These pharmacologic properties make it an ideal agent for treating central nervous system malignancies.

Originator

Curator's Comment: The story of temozolomide starts in the late 1970s in Birmingham, where Professor Stevens was leading a team of researchers at Aston University.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Target ID: CHEMBL2311221
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
TEMODAR

Approved Use

Newly diagnosed glioblastoma multiforme (GBM) concomitantly with radiotherapy and then as maintenance treatment; Refractory anaplastic astrocytoma, patients who have experienced disease progression on a drug regimen containing nitrosourea and procarbazine

Launch Date

1999
Primary
TEMODAR

Approved Use

Newly diagnosed glioblastoma multiforme (GBM) concomitantly with radiotherapy and then as maintenance treatment; Refractory anaplastic astrocytoma, patients who have experienced disease progression on a drug regimen containing nitrosourea and procarbazine

Launch Date

1999
Primary
Unknown

Approved Use

Unknown
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
7.5 μg/mL
150 mg/m² single, oral
dose: 150 mg/m²
route of administration: Oral
experiment type: SINGLE
co-administered:
TEMOZOLOMIDE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
23.4 μg × h/mL
150 mg/m² single, oral
dose: 150 mg/m²
route of administration: Oral
experiment type: SINGLE
co-administered:
TEMOZOLOMIDE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
1.8 h
150 mg/m² single, oral
dose: 150 mg/m²
route of administration: Oral
experiment type: SINGLE
co-administered:
TEMOZOLOMIDE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
1.87 h
200 mg/m^2 single, oral
dose: 200 mg/m^2
route of administration: oral
experiment type: single
co-administered:
TEMOZOLOMIDE plasma
Homo sapiens
1.89 h
200 mg/m^2 single, oral
dose: 200 mg/m^2
route of administration: oral
experiment type: single
co-administered:
TEMOZOLOMIDE plasma
Homo sapiens
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
85%
150 mg/m² single, oral
dose: 150 mg/m²
route of administration: Oral
experiment type: SINGLE
co-administered:
TEMOZOLOMIDE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
1000 mg/m2 1 times / 4 weeks multiple, oral
Highest studied dose
Dose: 1000 mg/m2, 1 times / 4 weeks
Route: oral
Route: multiple
Dose: 1000 mg/m2, 1 times / 4 weeks
Sources:
unhealthy, adult
n = 6
Health Status: unhealthy
Condition: solid tumors
Age Group: adult
Population Size: 6
Sources:
Other AEs: Neutropenia, Thrombocytopenia...
Other AEs:
Neutropenia (grade 4, 2 patients)
Thrombocytopenia (grade 4, 1 patient)
Sources:
250 mg/m2 1 times / day multiple, oral
Highest studied dose
Dose: 250 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 250 mg/m2, 1 times / day
Sources:
unhealthy, adult
n = 3
Health Status: unhealthy
Condition: malignancies, refractory or relapsing
Age Group: adult
Population Size: 3
Sources:
DLT: Thrombocytopenia...
Other AEs: Anaemia, Neutropenia...
Dose limiting toxicities:
Thrombocytopenia (grade 4, 2 patients)
Other AEs:
Anaemia (grade 3, 1 patient)
Neutropenia (grade 3, 2 patients)
Sources:
200 mg/m2 1 times / day multiple, oral
MTD
Dose: 200 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg/m2, 1 times / day
Sources:
unhealthy, adult
n = 6
Health Status: unhealthy
Condition: malignancies, refractory or relapsing
Age Group: adult
Population Size: 6
Sources:
Other AEs: Anaemia...
Other AEs:
Anaemia (grade 4, 1 patient)
Sources:
750 mg/m2 1 times / 4 weeks multiple, oral
MTD
Dose: 750 mg/m2, 1 times / 4 weeks
Route: oral
Route: multiple
Dose: 750 mg/m2, 1 times / 4 weeks
Sources:
unhealthy, adult
n = 6
Health Status: unhealthy
Condition: solid tumors
Age Group: adult
Population Size: 6
Sources:
Other AEs: Neutropenia, Thrombocytopenia...
Other AEs:
Neutropenia (grade 4, 1 patient)
Thrombocytopenia (grade 3, 2 patients)
Sources:
150 mg/m2 1 times / day multiple, oral
Recommended
Dose: 150 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 150 mg/m2, 1 times / day
Sources:
unhealthy, adult
n = 224
Health Status: unhealthy
Condition: glioblastoma multiforme, newly diagnosed
Age Group: adult
Population Size: 224
Sources:
Other AEs: Anorexia, Dizziness...
Other AEs:
Anorexia (all grades, 27%)
Dizziness (all grades, 5%)
Fatigue (all grades, 61%)
Headache (all grades, 23%)
Weakness (all grades, 7%)
Confusion (all grades, 5%)
Convulsions (all grades, 11%)
Memory impairment (all grades, 7%)
Vision blurred (all grades, 8%)
Allergic reaction (all grades, 3%)
Abdominal pain (all grades, 5%)
Constipation (all grades, 22%)
Diarrhea (all grades, 10%)
Nausea (all grades, 49%)
Stomatitis (all grades, 9%)
Vomiting (all grades, 29%)
Radiation injury NOS (all grades, 2%)
Arthralgia (all grades, 6%)
Thrombocytopenia (all grades, 8%)
Insomnia (all grades, 4%)
Coughing (all grades, 8%)
Dyspnea (all grades, 5%)
Alopecia (all grades, 55%)
Dry skin (all grades, 5%)
Erythema (all grades, 1%)
Pruritus (all grades, 5%)
Rash (all grades, 13%)
Taste perversion (all grades, 5%)
Sources:
150 mg/m2 1 times / day multiple, oral
Recommended
Dose: 150 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 150 mg/m2, 1 times / day
Sources:
unhealthy, adult
n = 158
Health Status: unhealthy
Condition: anaplastic astrocytoma
Age Group: adult
Population Size: 158
Sources:
Other AEs: Headache, Fatigue...
Other AEs:
Headache (all grades, 41%)
Fatigue (all grades, 34%)
Asthenia (all grades, 13%)
Fever (all grades, 13%)
Back pain (all grades, 8%)
Edema peripheral (all grades, 11%)
Convulsions (all grades, 23%)
Hemiparesis (all grades, 18%)
Dizziness (all grades, 12%)
Coordination abnormal (all grades, 11%)
Amnesia (all grades, 10%)
Insomnia (all grades, 10%)
Paresthesia (all grades, 9%)
Somnolence (all grades, 9%)
Paresis (all grades, 8%)
Urinary incontinence (all grades, 8%)
Ataxia (all grades, 8%)
Dysphasia (all grades, 7%)
Convulsions local (all grades, 6%)
Abnormal gait (all grades, 6%)
Confusion (all grades, 5%)
Adrenal hypercorticism (all grades, 8%)
Nausea (all grades, 53%)
Vomiting (all grades, 42%)
Constipation (all grades, 33%)
Diarrhea (all grades, 16%)
Abdominal pain (all grades, 9%)
Anorexia (all grades, 9%)
Weight increase (all grades, 5%)
Myalgia (all grades, 5%)
Anxiety (all grades, 7%)
Depression (all grades, 6%)
Breast pain female (all grades, 6%)
Infection viral (all grades, 11%)
Upper respiratory tract infection (all grades, 8%)
Pharyngitis (all grades, 8%)
Sinusitis (all grades, 6%)
Coughing (all grades, 5%)
Rash (all grades, 8%)
Pruritus (all grades, 8%)
Urinary tract infection (all grades, 8%)
Micturition frequency increased (all grades, 6%)
Diplopia (all grades, 5%)
Abnormal vision (all grades, 5%)
Sources:
75 mg/m2 1 times / day multiple, oral
Recommended
Dose: 75 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 75 mg/m2, 1 times / day
Sources:
unhealthy, adult
n = 288
Health Status: unhealthy
Condition: glioblastoma multiforme, newly diagnosed
Age Group: adult
Population Size: 288
Sources:
Other AEs: Anorexia, Dizziness...
Other AEs:
Anorexia (all grades, 19%)
Dizziness (all grades, 4%)
Fatigue (all grades, 54%)
Headache (all grades, 19%)
Weakness (all grades, 3%)
Confusion (all grades, 4%)
Convulsions (all grades, 6%)
Memory impairment (all grades, 3%)
Vision blurred (all grades, 9%)
Allergic reaction (all grades, 5%)
Abdominal pain (all grades, 2%)
Constipation (all grades, 18%)
Diarrhea (all grades, 6%)
Nausea (all grades, 36%)
Stomatitis (all grades, 7%)
Vomiting (all grades, 20%)
Radiation injury NOS (all grades, 7%)
Arthralgia (all grades, 2%)
Thrombocytopenia (all grades, 4%)
Insomnia (all grades, 5%)
Coughing (all grades, 5%)
Dyspnea (all grades, 4%)
Alopecia (all grades, 69%)
Dry skin (all grades, 2%)
Erythema (all grades, 5%)
Pruritus (all grades, 4%)
Rash (all grades, 19%)
Sources:
AEs

AEs

AESignificanceDosePopulation
Thrombocytopenia grade 4, 1 patient
1000 mg/m2 1 times / 4 weeks multiple, oral
Highest studied dose
Dose: 1000 mg/m2, 1 times / 4 weeks
Route: oral
Route: multiple
Dose: 1000 mg/m2, 1 times / 4 weeks
Sources:
unhealthy, adult
n = 6
Health Status: unhealthy
Condition: solid tumors
Age Group: adult
Population Size: 6
Sources:
Neutropenia grade 4, 2 patients
1000 mg/m2 1 times / 4 weeks multiple, oral
Highest studied dose
Dose: 1000 mg/m2, 1 times / 4 weeks
Route: oral
Route: multiple
Dose: 1000 mg/m2, 1 times / 4 weeks
Sources:
unhealthy, adult
n = 6
Health Status: unhealthy
Condition: solid tumors
Age Group: adult
Population Size: 6
Sources:
Anaemia grade 3, 1 patient
250 mg/m2 1 times / day multiple, oral
Highest studied dose
Dose: 250 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 250 mg/m2, 1 times / day
Sources:
unhealthy, adult
n = 3
Health Status: unhealthy
Condition: malignancies, refractory or relapsing
Age Group: adult
Population Size: 3
Sources:
Neutropenia grade 3, 2 patients
250 mg/m2 1 times / day multiple, oral
Highest studied dose
Dose: 250 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 250 mg/m2, 1 times / day
Sources:
unhealthy, adult
n = 3
Health Status: unhealthy
Condition: malignancies, refractory or relapsing
Age Group: adult
Population Size: 3
Sources:
Thrombocytopenia grade 4, 2 patients
DLT
250 mg/m2 1 times / day multiple, oral
Highest studied dose
Dose: 250 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 250 mg/m2, 1 times / day
Sources:
unhealthy, adult
n = 3
Health Status: unhealthy
Condition: malignancies, refractory or relapsing
Age Group: adult
Population Size: 3
Sources:
Anaemia grade 4, 1 patient
200 mg/m2 1 times / day multiple, oral
MTD
Dose: 200 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg/m2, 1 times / day
Sources:
unhealthy, adult
n = 6
Health Status: unhealthy
Condition: malignancies, refractory or relapsing
Age Group: adult
Population Size: 6
Sources:
Thrombocytopenia grade 3, 2 patients
750 mg/m2 1 times / 4 weeks multiple, oral
MTD
Dose: 750 mg/m2, 1 times / 4 weeks
Route: oral
Route: multiple
Dose: 750 mg/m2, 1 times / 4 weeks
Sources:
unhealthy, adult
n = 6
Health Status: unhealthy
Condition: solid tumors
Age Group: adult
Population Size: 6
Sources:
Neutropenia grade 4, 1 patient
750 mg/m2 1 times / 4 weeks multiple, oral
MTD
Dose: 750 mg/m2, 1 times / 4 weeks
Route: oral
Route: multiple
Dose: 750 mg/m2, 1 times / 4 weeks
Sources:
unhealthy, adult
n = 6
Health Status: unhealthy
Condition: solid tumors
Age Group: adult
Population Size: 6
Sources:
Erythema all grades, 1%
150 mg/m2 1 times / day multiple, oral
Recommended
Dose: 150 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 150 mg/m2, 1 times / day
Sources:
unhealthy, adult
n = 224
Health Status: unhealthy
Condition: glioblastoma multiforme, newly diagnosed
Age Group: adult
Population Size: 224
Sources:
Diarrhea all grades, 10%
150 mg/m2 1 times / day multiple, oral
Recommended
Dose: 150 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 150 mg/m2, 1 times / day
Sources:
unhealthy, adult
n = 224
Health Status: unhealthy
Condition: glioblastoma multiforme, newly diagnosed
Age Group: adult
Population Size: 224
Sources:
Convulsions all grades, 11%
150 mg/m2 1 times / day multiple, oral
Recommended
Dose: 150 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 150 mg/m2, 1 times / day
Sources:
unhealthy, adult
n = 224
Health Status: unhealthy
Condition: glioblastoma multiforme, newly diagnosed
Age Group: adult
Population Size: 224
Sources:
Rash all grades, 13%
150 mg/m2 1 times / day multiple, oral
Recommended
Dose: 150 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 150 mg/m2, 1 times / day
Sources:
unhealthy, adult
n = 224
Health Status: unhealthy
Condition: glioblastoma multiforme, newly diagnosed
Age Group: adult
Population Size: 224
Sources:
Radiation injury NOS all grades, 2%
150 mg/m2 1 times / day multiple, oral
Recommended
Dose: 150 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 150 mg/m2, 1 times / day
Sources:
unhealthy, adult
n = 224
Health Status: unhealthy
Condition: glioblastoma multiforme, newly diagnosed
Age Group: adult
Population Size: 224
Sources:
Constipation all grades, 22%
150 mg/m2 1 times / day multiple, oral
Recommended
Dose: 150 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 150 mg/m2, 1 times / day
Sources:
unhealthy, adult
n = 224
Health Status: unhealthy
Condition: glioblastoma multiforme, newly diagnosed
Age Group: adult
Population Size: 224
Sources:
Headache all grades, 23%
150 mg/m2 1 times / day multiple, oral
Recommended
Dose: 150 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 150 mg/m2, 1 times / day
Sources:
unhealthy, adult
n = 224
Health Status: unhealthy
Condition: glioblastoma multiforme, newly diagnosed
Age Group: adult
Population Size: 224
Sources:
Anorexia all grades, 27%
150 mg/m2 1 times / day multiple, oral
Recommended
Dose: 150 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 150 mg/m2, 1 times / day
Sources:
unhealthy, adult
n = 224
Health Status: unhealthy
Condition: glioblastoma multiforme, newly diagnosed
Age Group: adult
Population Size: 224
Sources:
Vomiting all grades, 29%
150 mg/m2 1 times / day multiple, oral
Recommended
Dose: 150 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 150 mg/m2, 1 times / day
Sources:
unhealthy, adult
n = 224
Health Status: unhealthy
Condition: glioblastoma multiforme, newly diagnosed
Age Group: adult
Population Size: 224
Sources:
Allergic reaction all grades, 3%
150 mg/m2 1 times / day multiple, oral
Recommended
Dose: 150 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 150 mg/m2, 1 times / day
Sources:
unhealthy, adult
n = 224
Health Status: unhealthy
Condition: glioblastoma multiforme, newly diagnosed
Age Group: adult
Population Size: 224
Sources:
Insomnia all grades, 4%
150 mg/m2 1 times / day multiple, oral
Recommended
Dose: 150 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 150 mg/m2, 1 times / day
Sources:
unhealthy, adult
n = 224
Health Status: unhealthy
Condition: glioblastoma multiforme, newly diagnosed
Age Group: adult
Population Size: 224
Sources:
Nausea all grades, 49%
150 mg/m2 1 times / day multiple, oral
Recommended
Dose: 150 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 150 mg/m2, 1 times / day
Sources:
unhealthy, adult
n = 224
Health Status: unhealthy
Condition: glioblastoma multiforme, newly diagnosed
Age Group: adult
Population Size: 224
Sources:
Abdominal pain all grades, 5%
150 mg/m2 1 times / day multiple, oral
Recommended
Dose: 150 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 150 mg/m2, 1 times / day
Sources:
unhealthy, adult
n = 224
Health Status: unhealthy
Condition: glioblastoma multiforme, newly diagnosed
Age Group: adult
Population Size: 224
Sources:
Confusion all grades, 5%
150 mg/m2 1 times / day multiple, oral
Recommended
Dose: 150 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 150 mg/m2, 1 times / day
Sources:
unhealthy, adult
n = 224
Health Status: unhealthy
Condition: glioblastoma multiforme, newly diagnosed
Age Group: adult
Population Size: 224
Sources:
Dizziness all grades, 5%
150 mg/m2 1 times / day multiple, oral
Recommended
Dose: 150 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 150 mg/m2, 1 times / day
Sources:
unhealthy, adult
n = 224
Health Status: unhealthy
Condition: glioblastoma multiforme, newly diagnosed
Age Group: adult
Population Size: 224
Sources:
Dry skin all grades, 5%
150 mg/m2 1 times / day multiple, oral
Recommended
Dose: 150 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 150 mg/m2, 1 times / day
Sources:
unhealthy, adult
n = 224
Health Status: unhealthy
Condition: glioblastoma multiforme, newly diagnosed
Age Group: adult
Population Size: 224
Sources:
Dyspnea all grades, 5%
150 mg/m2 1 times / day multiple, oral
Recommended
Dose: 150 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 150 mg/m2, 1 times / day
Sources:
unhealthy, adult
n = 224
Health Status: unhealthy
Condition: glioblastoma multiforme, newly diagnosed
Age Group: adult
Population Size: 224
Sources:
Pruritus all grades, 5%
150 mg/m2 1 times / day multiple, oral
Recommended
Dose: 150 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 150 mg/m2, 1 times / day
Sources:
unhealthy, adult
n = 224
Health Status: unhealthy
Condition: glioblastoma multiforme, newly diagnosed
Age Group: adult
Population Size: 224
Sources:
Taste perversion all grades, 5%
150 mg/m2 1 times / day multiple, oral
Recommended
Dose: 150 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 150 mg/m2, 1 times / day
Sources:
unhealthy, adult
n = 224
Health Status: unhealthy
Condition: glioblastoma multiforme, newly diagnosed
Age Group: adult
Population Size: 224
Sources:
Alopecia all grades, 55%
150 mg/m2 1 times / day multiple, oral
Recommended
Dose: 150 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 150 mg/m2, 1 times / day
Sources:
unhealthy, adult
n = 224
Health Status: unhealthy
Condition: glioblastoma multiforme, newly diagnosed
Age Group: adult
Population Size: 224
Sources:
Arthralgia all grades, 6%
150 mg/m2 1 times / day multiple, oral
Recommended
Dose: 150 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 150 mg/m2, 1 times / day
Sources:
unhealthy, adult
n = 224
Health Status: unhealthy
Condition: glioblastoma multiforme, newly diagnosed
Age Group: adult
Population Size: 224
Sources:
Fatigue all grades, 61%
150 mg/m2 1 times / day multiple, oral
Recommended
Dose: 150 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 150 mg/m2, 1 times / day
Sources:
unhealthy, adult
n = 224
Health Status: unhealthy
Condition: glioblastoma multiforme, newly diagnosed
Age Group: adult
Population Size: 224
Sources:
Memory impairment all grades, 7%
150 mg/m2 1 times / day multiple, oral
Recommended
Dose: 150 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 150 mg/m2, 1 times / day
Sources:
unhealthy, adult
n = 224
Health Status: unhealthy
Condition: glioblastoma multiforme, newly diagnosed
Age Group: adult
Population Size: 224
Sources:
Weakness all grades, 7%
150 mg/m2 1 times / day multiple, oral
Recommended
Dose: 150 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 150 mg/m2, 1 times / day
Sources:
unhealthy, adult
n = 224
Health Status: unhealthy
Condition: glioblastoma multiforme, newly diagnosed
Age Group: adult
Population Size: 224
Sources:
Coughing all grades, 8%
150 mg/m2 1 times / day multiple, oral
Recommended
Dose: 150 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 150 mg/m2, 1 times / day
Sources:
unhealthy, adult
n = 224
Health Status: unhealthy
Condition: glioblastoma multiforme, newly diagnosed
Age Group: adult
Population Size: 224
Sources:
Thrombocytopenia all grades, 8%
150 mg/m2 1 times / day multiple, oral
Recommended
Dose: 150 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 150 mg/m2, 1 times / day
Sources:
unhealthy, adult
n = 224
Health Status: unhealthy
Condition: glioblastoma multiforme, newly diagnosed
Age Group: adult
Population Size: 224
Sources:
Vision blurred all grades, 8%
150 mg/m2 1 times / day multiple, oral
Recommended
Dose: 150 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 150 mg/m2, 1 times / day
Sources:
unhealthy, adult
n = 224
Health Status: unhealthy
Condition: glioblastoma multiforme, newly diagnosed
Age Group: adult
Population Size: 224
Sources:
Stomatitis all grades, 9%
150 mg/m2 1 times / day multiple, oral
Recommended
Dose: 150 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 150 mg/m2, 1 times / day
Sources:
unhealthy, adult
n = 224
Health Status: unhealthy
Condition: glioblastoma multiforme, newly diagnosed
Age Group: adult
Population Size: 224
Sources:
Amnesia all grades, 10%
150 mg/m2 1 times / day multiple, oral
Recommended
Dose: 150 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 150 mg/m2, 1 times / day
Sources:
unhealthy, adult
n = 158
Health Status: unhealthy
Condition: anaplastic astrocytoma
Age Group: adult
Population Size: 158
Sources:
Insomnia all grades, 10%
150 mg/m2 1 times / day multiple, oral
Recommended
Dose: 150 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 150 mg/m2, 1 times / day
Sources:
unhealthy, adult
n = 158
Health Status: unhealthy
Condition: anaplastic astrocytoma
Age Group: adult
Population Size: 158
Sources:
Coordination abnormal all grades, 11%
150 mg/m2 1 times / day multiple, oral
Recommended
Dose: 150 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 150 mg/m2, 1 times / day
Sources:
unhealthy, adult
n = 158
Health Status: unhealthy
Condition: anaplastic astrocytoma
Age Group: adult
Population Size: 158
Sources:
Edema peripheral all grades, 11%
150 mg/m2 1 times / day multiple, oral
Recommended
Dose: 150 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 150 mg/m2, 1 times / day
Sources:
unhealthy, adult
n = 158
Health Status: unhealthy
Condition: anaplastic astrocytoma
Age Group: adult
Population Size: 158
Sources:
Infection viral all grades, 11%
150 mg/m2 1 times / day multiple, oral
Recommended
Dose: 150 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 150 mg/m2, 1 times / day
Sources:
unhealthy, adult
n = 158
Health Status: unhealthy
Condition: anaplastic astrocytoma
Age Group: adult
Population Size: 158
Sources:
Dizziness all grades, 12%
150 mg/m2 1 times / day multiple, oral
Recommended
Dose: 150 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 150 mg/m2, 1 times / day
Sources:
unhealthy, adult
n = 158
Health Status: unhealthy
Condition: anaplastic astrocytoma
Age Group: adult
Population Size: 158
Sources:
Asthenia all grades, 13%
150 mg/m2 1 times / day multiple, oral
Recommended
Dose: 150 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 150 mg/m2, 1 times / day
Sources:
unhealthy, adult
n = 158
Health Status: unhealthy
Condition: anaplastic astrocytoma
Age Group: adult
Population Size: 158
Sources:
Fever all grades, 13%
150 mg/m2 1 times / day multiple, oral
Recommended
Dose: 150 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 150 mg/m2, 1 times / day
Sources:
unhealthy, adult
n = 158
Health Status: unhealthy
Condition: anaplastic astrocytoma
Age Group: adult
Population Size: 158
Sources:
Diarrhea all grades, 16%
150 mg/m2 1 times / day multiple, oral
Recommended
Dose: 150 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 150 mg/m2, 1 times / day
Sources:
unhealthy, adult
n = 158
Health Status: unhealthy
Condition: anaplastic astrocytoma
Age Group: adult
Population Size: 158
Sources:
Hemiparesis all grades, 18%
150 mg/m2 1 times / day multiple, oral
Recommended
Dose: 150 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 150 mg/m2, 1 times / day
Sources:
unhealthy, adult
n = 158
Health Status: unhealthy
Condition: anaplastic astrocytoma
Age Group: adult
Population Size: 158
Sources:
Convulsions all grades, 23%
150 mg/m2 1 times / day multiple, oral
Recommended
Dose: 150 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 150 mg/m2, 1 times / day
Sources:
unhealthy, adult
n = 158
Health Status: unhealthy
Condition: anaplastic astrocytoma
Age Group: adult
Population Size: 158
Sources:
Constipation all grades, 33%
150 mg/m2 1 times / day multiple, oral
Recommended
Dose: 150 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 150 mg/m2, 1 times / day
Sources:
unhealthy, adult
n = 158
Health Status: unhealthy
Condition: anaplastic astrocytoma
Age Group: adult
Population Size: 158
Sources:
Fatigue all grades, 34%
150 mg/m2 1 times / day multiple, oral
Recommended
Dose: 150 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 150 mg/m2, 1 times / day
Sources:
unhealthy, adult
n = 158
Health Status: unhealthy
Condition: anaplastic astrocytoma
Age Group: adult
Population Size: 158
Sources:
Headache all grades, 41%
150 mg/m2 1 times / day multiple, oral
Recommended
Dose: 150 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 150 mg/m2, 1 times / day
Sources:
unhealthy, adult
n = 158
Health Status: unhealthy
Condition: anaplastic astrocytoma
Age Group: adult
Population Size: 158
Sources:
Vomiting all grades, 42%
150 mg/m2 1 times / day multiple, oral
Recommended
Dose: 150 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 150 mg/m2, 1 times / day
Sources:
unhealthy, adult
n = 158
Health Status: unhealthy
Condition: anaplastic astrocytoma
Age Group: adult
Population Size: 158
Sources:
Abnormal vision all grades, 5%
150 mg/m2 1 times / day multiple, oral
Recommended
Dose: 150 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 150 mg/m2, 1 times / day
Sources:
unhealthy, adult
n = 158
Health Status: unhealthy
Condition: anaplastic astrocytoma
Age Group: adult
Population Size: 158
Sources:
Confusion all grades, 5%
150 mg/m2 1 times / day multiple, oral
Recommended
Dose: 150 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 150 mg/m2, 1 times / day
Sources:
unhealthy, adult
n = 158
Health Status: unhealthy
Condition: anaplastic astrocytoma
Age Group: adult
Population Size: 158
Sources:
Coughing all grades, 5%
150 mg/m2 1 times / day multiple, oral
Recommended
Dose: 150 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 150 mg/m2, 1 times / day
Sources:
unhealthy, adult
n = 158
Health Status: unhealthy
Condition: anaplastic astrocytoma
Age Group: adult
Population Size: 158
Sources:
Diplopia all grades, 5%
150 mg/m2 1 times / day multiple, oral
Recommended
Dose: 150 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 150 mg/m2, 1 times / day
Sources:
unhealthy, adult
n = 158
Health Status: unhealthy
Condition: anaplastic astrocytoma
Age Group: adult
Population Size: 158
Sources:
Myalgia all grades, 5%
150 mg/m2 1 times / day multiple, oral
Recommended
Dose: 150 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 150 mg/m2, 1 times / day
Sources:
unhealthy, adult
n = 158
Health Status: unhealthy
Condition: anaplastic astrocytoma
Age Group: adult
Population Size: 158
Sources:
Weight increase all grades, 5%
150 mg/m2 1 times / day multiple, oral
Recommended
Dose: 150 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 150 mg/m2, 1 times / day
Sources:
unhealthy, adult
n = 158
Health Status: unhealthy
Condition: anaplastic astrocytoma
Age Group: adult
Population Size: 158
Sources:
Nausea all grades, 53%
150 mg/m2 1 times / day multiple, oral
Recommended
Dose: 150 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 150 mg/m2, 1 times / day
Sources:
unhealthy, adult
n = 158
Health Status: unhealthy
Condition: anaplastic astrocytoma
Age Group: adult
Population Size: 158
Sources:
Abnormal gait all grades, 6%
150 mg/m2 1 times / day multiple, oral
Recommended
Dose: 150 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 150 mg/m2, 1 times / day
Sources:
unhealthy, adult
n = 158
Health Status: unhealthy
Condition: anaplastic astrocytoma
Age Group: adult
Population Size: 158
Sources:
Breast pain female all grades, 6%
150 mg/m2 1 times / day multiple, oral
Recommended
Dose: 150 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 150 mg/m2, 1 times / day
Sources:
unhealthy, adult
n = 158
Health Status: unhealthy
Condition: anaplastic astrocytoma
Age Group: adult
Population Size: 158
Sources:
Convulsions local all grades, 6%
150 mg/m2 1 times / day multiple, oral
Recommended
Dose: 150 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 150 mg/m2, 1 times / day
Sources:
unhealthy, adult
n = 158
Health Status: unhealthy
Condition: anaplastic astrocytoma
Age Group: adult
Population Size: 158
Sources:
Depression all grades, 6%
150 mg/m2 1 times / day multiple, oral
Recommended
Dose: 150 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 150 mg/m2, 1 times / day
Sources:
unhealthy, adult
n = 158
Health Status: unhealthy
Condition: anaplastic astrocytoma
Age Group: adult
Population Size: 158
Sources:
Micturition frequency increased all grades, 6%
150 mg/m2 1 times / day multiple, oral
Recommended
Dose: 150 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 150 mg/m2, 1 times / day
Sources:
unhealthy, adult
n = 158
Health Status: unhealthy
Condition: anaplastic astrocytoma
Age Group: adult
Population Size: 158
Sources:
Sinusitis all grades, 6%
150 mg/m2 1 times / day multiple, oral
Recommended
Dose: 150 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 150 mg/m2, 1 times / day
Sources:
unhealthy, adult
n = 158
Health Status: unhealthy
Condition: anaplastic astrocytoma
Age Group: adult
Population Size: 158
Sources:
Anxiety all grades, 7%
150 mg/m2 1 times / day multiple, oral
Recommended
Dose: 150 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 150 mg/m2, 1 times / day
Sources:
unhealthy, adult
n = 158
Health Status: unhealthy
Condition: anaplastic astrocytoma
Age Group: adult
Population Size: 158
Sources:
Dysphasia all grades, 7%
150 mg/m2 1 times / day multiple, oral
Recommended
Dose: 150 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 150 mg/m2, 1 times / day
Sources:
unhealthy, adult
n = 158
Health Status: unhealthy
Condition: anaplastic astrocytoma
Age Group: adult
Population Size: 158
Sources:
Adrenal hypercorticism all grades, 8%
150 mg/m2 1 times / day multiple, oral
Recommended
Dose: 150 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 150 mg/m2, 1 times / day
Sources:
unhealthy, adult
n = 158
Health Status: unhealthy
Condition: anaplastic astrocytoma
Age Group: adult
Population Size: 158
Sources:
Ataxia all grades, 8%
150 mg/m2 1 times / day multiple, oral
Recommended
Dose: 150 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 150 mg/m2, 1 times / day
Sources:
unhealthy, adult
n = 158
Health Status: unhealthy
Condition: anaplastic astrocytoma
Age Group: adult
Population Size: 158
Sources:
Back pain all grades, 8%
150 mg/m2 1 times / day multiple, oral
Recommended
Dose: 150 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 150 mg/m2, 1 times / day
Sources:
unhealthy, adult
n = 158
Health Status: unhealthy
Condition: anaplastic astrocytoma
Age Group: adult
Population Size: 158
Sources:
Paresis all grades, 8%
150 mg/m2 1 times / day multiple, oral
Recommended
Dose: 150 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 150 mg/m2, 1 times / day
Sources:
unhealthy, adult
n = 158
Health Status: unhealthy
Condition: anaplastic astrocytoma
Age Group: adult
Population Size: 158
Sources:
Pharyngitis all grades, 8%
150 mg/m2 1 times / day multiple, oral
Recommended
Dose: 150 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 150 mg/m2, 1 times / day
Sources:
unhealthy, adult
n = 158
Health Status: unhealthy
Condition: anaplastic astrocytoma
Age Group: adult
Population Size: 158
Sources:
Pruritus all grades, 8%
150 mg/m2 1 times / day multiple, oral
Recommended
Dose: 150 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 150 mg/m2, 1 times / day
Sources:
unhealthy, adult
n = 158
Health Status: unhealthy
Condition: anaplastic astrocytoma
Age Group: adult
Population Size: 158
Sources:
Rash all grades, 8%
150 mg/m2 1 times / day multiple, oral
Recommended
Dose: 150 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 150 mg/m2, 1 times / day
Sources:
unhealthy, adult
n = 158
Health Status: unhealthy
Condition: anaplastic astrocytoma
Age Group: adult
Population Size: 158
Sources:
Upper respiratory tract infection all grades, 8%
150 mg/m2 1 times / day multiple, oral
Recommended
Dose: 150 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 150 mg/m2, 1 times / day
Sources:
unhealthy, adult
n = 158
Health Status: unhealthy
Condition: anaplastic astrocytoma
Age Group: adult
Population Size: 158
Sources:
Urinary incontinence all grades, 8%
150 mg/m2 1 times / day multiple, oral
Recommended
Dose: 150 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 150 mg/m2, 1 times / day
Sources:
unhealthy, adult
n = 158
Health Status: unhealthy
Condition: anaplastic astrocytoma
Age Group: adult
Population Size: 158
Sources:
Urinary tract infection all grades, 8%
150 mg/m2 1 times / day multiple, oral
Recommended
Dose: 150 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 150 mg/m2, 1 times / day
Sources:
unhealthy, adult
n = 158
Health Status: unhealthy
Condition: anaplastic astrocytoma
Age Group: adult
Population Size: 158
Sources:
Abdominal pain all grades, 9%
150 mg/m2 1 times / day multiple, oral
Recommended
Dose: 150 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 150 mg/m2, 1 times / day
Sources:
unhealthy, adult
n = 158
Health Status: unhealthy
Condition: anaplastic astrocytoma
Age Group: adult
Population Size: 158
Sources:
Anorexia all grades, 9%
150 mg/m2 1 times / day multiple, oral
Recommended
Dose: 150 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 150 mg/m2, 1 times / day
Sources:
unhealthy, adult
n = 158
Health Status: unhealthy
Condition: anaplastic astrocytoma
Age Group: adult
Population Size: 158
Sources:
Paresthesia all grades, 9%
150 mg/m2 1 times / day multiple, oral
Recommended
Dose: 150 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 150 mg/m2, 1 times / day
Sources:
unhealthy, adult
n = 158
Health Status: unhealthy
Condition: anaplastic astrocytoma
Age Group: adult
Population Size: 158
Sources:
Somnolence all grades, 9%
150 mg/m2 1 times / day multiple, oral
Recommended
Dose: 150 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 150 mg/m2, 1 times / day
Sources:
unhealthy, adult
n = 158
Health Status: unhealthy
Condition: anaplastic astrocytoma
Age Group: adult
Population Size: 158
Sources:
Constipation all grades, 18%
75 mg/m2 1 times / day multiple, oral
Recommended
Dose: 75 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 75 mg/m2, 1 times / day
Sources:
unhealthy, adult
n = 288
Health Status: unhealthy
Condition: glioblastoma multiforme, newly diagnosed
Age Group: adult
Population Size: 288
Sources:
Anorexia all grades, 19%
75 mg/m2 1 times / day multiple, oral
Recommended
Dose: 75 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 75 mg/m2, 1 times / day
Sources:
unhealthy, adult
n = 288
Health Status: unhealthy
Condition: glioblastoma multiforme, newly diagnosed
Age Group: adult
Population Size: 288
Sources:
Headache all grades, 19%
75 mg/m2 1 times / day multiple, oral
Recommended
Dose: 75 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 75 mg/m2, 1 times / day
Sources:
unhealthy, adult
n = 288
Health Status: unhealthy
Condition: glioblastoma multiforme, newly diagnosed
Age Group: adult
Population Size: 288
Sources:
Rash all grades, 19%
75 mg/m2 1 times / day multiple, oral
Recommended
Dose: 75 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 75 mg/m2, 1 times / day
Sources:
unhealthy, adult
n = 288
Health Status: unhealthy
Condition: glioblastoma multiforme, newly diagnosed
Age Group: adult
Population Size: 288
Sources:
Abdominal pain all grades, 2%
75 mg/m2 1 times / day multiple, oral
Recommended
Dose: 75 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 75 mg/m2, 1 times / day
Sources:
unhealthy, adult
n = 288
Health Status: unhealthy
Condition: glioblastoma multiforme, newly diagnosed
Age Group: adult
Population Size: 288
Sources:
Arthralgia all grades, 2%
75 mg/m2 1 times / day multiple, oral
Recommended
Dose: 75 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 75 mg/m2, 1 times / day
Sources:
unhealthy, adult
n = 288
Health Status: unhealthy
Condition: glioblastoma multiforme, newly diagnosed
Age Group: adult
Population Size: 288
Sources:
Dry skin all grades, 2%
75 mg/m2 1 times / day multiple, oral
Recommended
Dose: 75 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 75 mg/m2, 1 times / day
Sources:
unhealthy, adult
n = 288
Health Status: unhealthy
Condition: glioblastoma multiforme, newly diagnosed
Age Group: adult
Population Size: 288
Sources:
Vomiting all grades, 20%
75 mg/m2 1 times / day multiple, oral
Recommended
Dose: 75 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 75 mg/m2, 1 times / day
Sources:
unhealthy, adult
n = 288
Health Status: unhealthy
Condition: glioblastoma multiforme, newly diagnosed
Age Group: adult
Population Size: 288
Sources:
Memory impairment all grades, 3%
75 mg/m2 1 times / day multiple, oral
Recommended
Dose: 75 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 75 mg/m2, 1 times / day
Sources:
unhealthy, adult
n = 288
Health Status: unhealthy
Condition: glioblastoma multiforme, newly diagnosed
Age Group: adult
Population Size: 288
Sources:
Weakness all grades, 3%
75 mg/m2 1 times / day multiple, oral
Recommended
Dose: 75 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 75 mg/m2, 1 times / day
Sources:
unhealthy, adult
n = 288
Health Status: unhealthy
Condition: glioblastoma multiforme, newly diagnosed
Age Group: adult
Population Size: 288
Sources:
Nausea all grades, 36%
75 mg/m2 1 times / day multiple, oral
Recommended
Dose: 75 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 75 mg/m2, 1 times / day
Sources:
unhealthy, adult
n = 288
Health Status: unhealthy
Condition: glioblastoma multiforme, newly diagnosed
Age Group: adult
Population Size: 288
Sources:
Confusion all grades, 4%
75 mg/m2 1 times / day multiple, oral
Recommended
Dose: 75 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 75 mg/m2, 1 times / day
Sources:
unhealthy, adult
n = 288
Health Status: unhealthy
Condition: glioblastoma multiforme, newly diagnosed
Age Group: adult
Population Size: 288
Sources:
Dizziness all grades, 4%
75 mg/m2 1 times / day multiple, oral
Recommended
Dose: 75 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 75 mg/m2, 1 times / day
Sources:
unhealthy, adult
n = 288
Health Status: unhealthy
Condition: glioblastoma multiforme, newly diagnosed
Age Group: adult
Population Size: 288
Sources:
Dyspnea all grades, 4%
75 mg/m2 1 times / day multiple, oral
Recommended
Dose: 75 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 75 mg/m2, 1 times / day
Sources:
unhealthy, adult
n = 288
Health Status: unhealthy
Condition: glioblastoma multiforme, newly diagnosed
Age Group: adult
Population Size: 288
Sources:
Pruritus all grades, 4%
75 mg/m2 1 times / day multiple, oral
Recommended
Dose: 75 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 75 mg/m2, 1 times / day
Sources:
unhealthy, adult
n = 288
Health Status: unhealthy
Condition: glioblastoma multiforme, newly diagnosed
Age Group: adult
Population Size: 288
Sources:
Thrombocytopenia all grades, 4%
75 mg/m2 1 times / day multiple, oral
Recommended
Dose: 75 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 75 mg/m2, 1 times / day
Sources:
unhealthy, adult
n = 288
Health Status: unhealthy
Condition: glioblastoma multiforme, newly diagnosed
Age Group: adult
Population Size: 288
Sources:
Allergic reaction all grades, 5%
75 mg/m2 1 times / day multiple, oral
Recommended
Dose: 75 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 75 mg/m2, 1 times / day
Sources:
unhealthy, adult
n = 288
Health Status: unhealthy
Condition: glioblastoma multiforme, newly diagnosed
Age Group: adult
Population Size: 288
Sources:
Coughing all grades, 5%
75 mg/m2 1 times / day multiple, oral
Recommended
Dose: 75 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 75 mg/m2, 1 times / day
Sources:
unhealthy, adult
n = 288
Health Status: unhealthy
Condition: glioblastoma multiforme, newly diagnosed
Age Group: adult
Population Size: 288
Sources:
Erythema all grades, 5%
75 mg/m2 1 times / day multiple, oral
Recommended
Dose: 75 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 75 mg/m2, 1 times / day
Sources:
unhealthy, adult
n = 288
Health Status: unhealthy
Condition: glioblastoma multiforme, newly diagnosed
Age Group: adult
Population Size: 288
Sources:
Insomnia all grades, 5%
75 mg/m2 1 times / day multiple, oral
Recommended
Dose: 75 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 75 mg/m2, 1 times / day
Sources:
unhealthy, adult
n = 288
Health Status: unhealthy
Condition: glioblastoma multiforme, newly diagnosed
Age Group: adult
Population Size: 288
Sources:
Fatigue all grades, 54%
75 mg/m2 1 times / day multiple, oral
Recommended
Dose: 75 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 75 mg/m2, 1 times / day
Sources:
unhealthy, adult
n = 288
Health Status: unhealthy
Condition: glioblastoma multiforme, newly diagnosed
Age Group: adult
Population Size: 288
Sources:
Convulsions all grades, 6%
75 mg/m2 1 times / day multiple, oral
Recommended
Dose: 75 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 75 mg/m2, 1 times / day
Sources:
unhealthy, adult
n = 288
Health Status: unhealthy
Condition: glioblastoma multiforme, newly diagnosed
Age Group: adult
Population Size: 288
Sources:
Diarrhea all grades, 6%
75 mg/m2 1 times / day multiple, oral
Recommended
Dose: 75 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 75 mg/m2, 1 times / day
Sources:
unhealthy, adult
n = 288
Health Status: unhealthy
Condition: glioblastoma multiforme, newly diagnosed
Age Group: adult
Population Size: 288
Sources:
Alopecia all grades, 69%
75 mg/m2 1 times / day multiple, oral
Recommended
Dose: 75 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 75 mg/m2, 1 times / day
Sources:
unhealthy, adult
n = 288
Health Status: unhealthy
Condition: glioblastoma multiforme, newly diagnosed
Age Group: adult
Population Size: 288
Sources:
Radiation injury NOS all grades, 7%
75 mg/m2 1 times / day multiple, oral
Recommended
Dose: 75 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 75 mg/m2, 1 times / day
Sources:
unhealthy, adult
n = 288
Health Status: unhealthy
Condition: glioblastoma multiforme, newly diagnosed
Age Group: adult
Population Size: 288
Sources:
Stomatitis all grades, 7%
75 mg/m2 1 times / day multiple, oral
Recommended
Dose: 75 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 75 mg/m2, 1 times / day
Sources:
unhealthy, adult
n = 288
Health Status: unhealthy
Condition: glioblastoma multiforme, newly diagnosed
Age Group: adult
Population Size: 288
Sources:
Vision blurred all grades, 9%
75 mg/m2 1 times / day multiple, oral
Recommended
Dose: 75 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 75 mg/m2, 1 times / day
Sources:
unhealthy, adult
n = 288
Health Status: unhealthy
Condition: glioblastoma multiforme, newly diagnosed
Age Group: adult
Population Size: 288
Sources:
PubMed

PubMed

TitleDatePubMed
Temozolomide and treatment of malignant glioma.
2000 Jul
Late recurrence of a primitive neuro-ectodermal tumor.
2001
Effects of single or split exposure of leukemic cells to temozolomide, combined with poly(ADP-ribose) polymerase inhibitors on cell growth, chromosomal aberrations and base excision repair components.
2001 Apr
Temozolomide for treating brain metastases.
2001 Aug
Temozolomide in combination with other cytotoxic agents.
2001 Aug
New approaches for temozolomide therapy: use in newly diagnosed glioma.
2001 Aug
Adenovirally-mediated transfer of E2F-1 potentiates chemosensitivity of human glioma cells to temozolomide and BCNU.
2001 Aug
Treatment of brain metastases of malignant melanoma with temozolomide.
2001 Aug 23
Low-grade gliomas.
2001 Dec
Brain metastases from fallopian tube carcinoma responsive to intra-arterial carboplatin and intravenous etoposide: a case report.
2001 Dec
Multicenter phase II trial of temozolomide in patients with glioblastoma multiforme at first relapse.
2001 Feb
CCNU-dependent potentiation of TRAIL/Apo2L-induced apoptosis in human glioma cells is p53-independent but may involve enhanced cytochrome c release.
2001 Jul 12
Atypical teratoid/rhabdoid tumors in adult patients: case report and review of the literature.
2001 Mar
p53 effects both the duration of G2/M arrest and the fate of temozolomide-treated human glioblastoma cells.
2001 Mar 1
Enforced expression of wild-type p53 curtails the transcription of the O(6)-methylguanine-DNA methyltransferase gene in human tumor cells and enhances their sensitivity to alkylating agents.
2001 May
Synergy between methionine stress and chemotherapy in the treatment of brain tumor xenografts in athymic mice.
2001 May 15
New strategy developments in brain tumor therapy.
2001 Nov
Possible efficacy of temozolomide in a patient with gliomatosis cerebri.
2001 Nov 27
New perspectives for the diagnosis and treatment of oligodendroglioma.
2001 Oct
Targeting DNA mismatch repair for radiosensitization.
2001 Oct
Concomitant radiotherapy and metronomic temozolomide in pediatric high-risk brain tumors.
2002
Effect of temozolomide on central nervous system relapse in patients with advanced melanoma.
2002 Apr
Photodynamic therapy of DNA mismatch repair-deficient and -proficient tumour cells.
2002 Apr 8
Effect of O6-(4-bromothenyl)guanine on different temozolomide schedules in a human melanoma xenograft model.
2002 Aug 10
Treatment of newly diagnosed glioblastoma multiforme.
2002 Jul 15
Temozolomide plus thalidomide in patients with advanced melanoma: results of a dose-finding trial.
2002 Jun 1
Phase II trial of temozolomide plus the matrix metalloproteinase inhibitor, marimastat, in recurrent and progressive glioblastoma multiforme.
2002 Mar 1
Prevention of irradiation-induced glioma cell invasion by temozolomide involves caspase 3 activity and cleavage of focal adhesion kinase.
2002 Mar 15
Temozolomide as second-line chemotherapy for relapsed gliomas.
2002 May
Patents

Sample Use Guides

In Vivo Use Guide
Curator's Comment: Dosage of TEMODAR must be adjusted according to nadir neutrophil and platelet counts in the previous cycle and the neutrophil and platelet counts at the time of initiating the next cycle. For TEMODAR dosage calculations based on body surface area (BSA). Is used: 5 mg, 20 mg, 100 mg, 140 mg, 180 mg, and 250 mg capsules and 100 mg powder for injection
intravenous infusion over 90 minutes is the same as the dose for the oral capsule formulation. Bioequivalence has been established only when TEMODAR for Injection was given over 90 minutes.
Route of Administration: Intravenous
In Vitro Use Guide
Grade IV glioma cell lines SHG44 and U251 cells were treated with 100 µmol/LT EMOZOLOMIDE (TMZ)
Substance Class Chemical
Created
by admin
on Fri Dec 15 15:40:26 GMT 2023
Edited
by admin
on Fri Dec 15 15:40:26 GMT 2023
Record UNII
YF1K15M17Y
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
TEMOZOLOMIDE
EMA EPAR   INN   JAN   MART.   MI   ORANGE BOOK   USAN   USP-RS   VANDF   WHO-DD  
INN   USAN  
Official Name English
temozolomide [INN]
Common Name English
MK-7365
Common Name English
NSC-362856
Code English
TEMOZOLOMIDE [EMA EPAR]
Common Name English
CCRG-81045
Code English
M&B-39831
Code English
M-39831
Code English
TEMOZOLOMIDE [EP MONOGRAPH]
Common Name English
METHAZOLASTONE
Common Name English
SCH 52365
Code English
TEMOZOLOMIDE [JAN]
Common Name English
TEMOZOLOMIDE [USAN]
Common Name English
TEMOZOLOMIDE [ORANGE BOOK]
Common Name English
SCH-52365
Code English
3,4-Dihydro-3-methyl-4-oxoimidazo[5,1-d]-as-tetrazine-8-carboxamide
Common Name English
TEMOZOLOMIDE [USP MONOGRAPH]
Common Name English
IMIDAZO(5,1-D)-1,2,3,5-TETRAZINE-8-CARBOXAMIDE, 3,4-DIHYDRO-3-METHYL-4-OXO-
Systematic Name English
TEMOZOLOMIDE [USP-RS]
Common Name English
TEMOZOLOMIDE [MART.]
Common Name English
TEMODAL
Brand Name English
TEMOZOLOMIDE [MI]
Common Name English
Temozolomide [WHO-DD]
Common Name English
M&B 39831
Code English
TEMODAR
Brand Name English
TEMOZOLOMIDE [VANDF]
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C902
Created by admin on Fri Dec 15 15:40:26 GMT 2023 , Edited by admin on Fri Dec 15 15:40:26 GMT 2023
NDF-RT N0000175558
Created by admin on Fri Dec 15 15:40:26 GMT 2023 , Edited by admin on Fri Dec 15 15:40:26 GMT 2023
WHO-ATC L01AX03
Created by admin on Fri Dec 15 15:40:26 GMT 2023 , Edited by admin on Fri Dec 15 15:40:26 GMT 2023
NDF-RT N0000000236
Created by admin on Fri Dec 15 15:40:26 GMT 2023 , Edited by admin on Fri Dec 15 15:40:26 GMT 2023
FDA ORPHAN DRUG 116798
Created by admin on Fri Dec 15 15:40:26 GMT 2023 , Edited by admin on Fri Dec 15 15:40:26 GMT 2023
EMA ASSESSMENT REPORTS TEMOZOLOMIDE SUN (AUTHORIZED: GLIOMA, GLIOBLASTOMA)
Created by admin on Fri Dec 15 15:40:26 GMT 2023 , Edited by admin on Fri Dec 15 15:40:26 GMT 2023
FDA ORPHAN DRUG 895222
Created by admin on Fri Dec 15 15:40:26 GMT 2023 , Edited by admin on Fri Dec 15 15:40:26 GMT 2023
EMA ASSESSMENT REPORTS TEMOZOLOMIDE TEVA (AUTHORIZED: GLIOMA, GLIOBLASTOMA)
Created by admin on Fri Dec 15 15:40:26 GMT 2023 , Edited by admin on Fri Dec 15 15:40:26 GMT 2023
EMA ASSESSMENT REPORTS TEMOZOLOMIDE SANDOZ (AUTHORIZED: GLIOMA, GLIOBLASTOMA)
Created by admin on Fri Dec 15 15:40:26 GMT 2023 , Edited by admin on Fri Dec 15 15:40:26 GMT 2023
EMA ASSESSMENT REPORTS TEMOZOLOMIDE HEXAL (AUTHORIZED: GLIOMA, GLIOBLASTOMA)
Created by admin on Fri Dec 15 15:40:26 GMT 2023 , Edited by admin on Fri Dec 15 15:40:26 GMT 2023
FDA ORPHAN DRUG 193904
Created by admin on Fri Dec 15 15:40:26 GMT 2023 , Edited by admin on Fri Dec 15 15:40:26 GMT 2023
WHO-VATC QL01AX03
Created by admin on Fri Dec 15 15:40:26 GMT 2023 , Edited by admin on Fri Dec 15 15:40:26 GMT 2023
EMA ASSESSMENT REPORTS TEMOMEDAC (AUTHORIZED: GLIOMA, GLIOBLASTOMA)
Created by admin on Fri Dec 15 15:40:26 GMT 2023 , Edited by admin on Fri Dec 15 15:40:26 GMT 2023
FDA ORPHAN DRUG 453314
Created by admin on Fri Dec 15 15:40:26 GMT 2023 , Edited by admin on Fri Dec 15 15:40:26 GMT 2023
EU-Orphan Drug EU/3/16/1733
Created by admin on Fri Dec 15 15:40:26 GMT 2023 , Edited by admin on Fri Dec 15 15:40:26 GMT 2023
FDA ORPHAN DRUG 497215
Created by admin on Fri Dec 15 15:40:26 GMT 2023 , Edited by admin on Fri Dec 15 15:40:26 GMT 2023
EMA ASSESSMENT REPORTS TEMODAL (AUTHORIZED: GLIOMA, GLIOBLASTOMA)
Created by admin on Fri Dec 15 15:40:26 GMT 2023 , Edited by admin on Fri Dec 15 15:40:26 GMT 2023
FDA ORPHAN DRUG 698519
Created by admin on Fri Dec 15 15:40:26 GMT 2023 , Edited by admin on Fri Dec 15 15:40:26 GMT 2023
LIVERTOX NBK548816
Created by admin on Fri Dec 15 15:40:26 GMT 2023 , Edited by admin on Fri Dec 15 15:40:26 GMT 2023
EMA ASSESSMENT REPORTS TEMOZOLOMIDE ACCORD (AUTHORIZED: GLIOMA, GLIOBLASTOMA
Created by admin on Fri Dec 15 15:40:26 GMT 2023 , Edited by admin on Fri Dec 15 15:40:26 GMT 2023
FDA ORPHAN DRUG 117198
Created by admin on Fri Dec 15 15:40:26 GMT 2023 , Edited by admin on Fri Dec 15 15:40:26 GMT 2023
Code System Code Type Description
EPA CompTox
DTXSID5043714
Created by admin on Fri Dec 15 15:40:26 GMT 2023 , Edited by admin on Fri Dec 15 15:40:26 GMT 2023
PRIMARY
MESH
C047246
Created by admin on Fri Dec 15 15:40:26 GMT 2023 , Edited by admin on Fri Dec 15 15:40:26 GMT 2023
PRIMARY
RXCUI
37776
Created by admin on Fri Dec 15 15:40:26 GMT 2023 , Edited by admin on Fri Dec 15 15:40:26 GMT 2023
PRIMARY RxNorm
CAS
85622-93-1
Created by admin on Fri Dec 15 15:40:26 GMT 2023 , Edited by admin on Fri Dec 15 15:40:26 GMT 2023
PRIMARY
USAN
LL-53
Created by admin on Fri Dec 15 15:40:26 GMT 2023 , Edited by admin on Fri Dec 15 15:40:26 GMT 2023
PRIMARY
RS_ITEM_NUM
1643543
Created by admin on Fri Dec 15 15:40:26 GMT 2023 , Edited by admin on Fri Dec 15 15:40:26 GMT 2023
PRIMARY
EVMPD
SUB10889MIG
Created by admin on Fri Dec 15 15:40:26 GMT 2023 , Edited by admin on Fri Dec 15 15:40:26 GMT 2023
PRIMARY
ChEMBL
CHEMBL810
Created by admin on Fri Dec 15 15:40:26 GMT 2023 , Edited by admin on Fri Dec 15 15:40:26 GMT 2023
PRIMARY
DRUG CENTRAL
2589
Created by admin on Fri Dec 15 15:40:26 GMT 2023 , Edited by admin on Fri Dec 15 15:40:26 GMT 2023
PRIMARY
LACTMED
Temozolamide
Created by admin on Fri Dec 15 15:40:26 GMT 2023 , Edited by admin on Fri Dec 15 15:40:26 GMT 2023
PRIMARY
FDA UNII
YF1K15M17Y
Created by admin on Fri Dec 15 15:40:26 GMT 2023 , Edited by admin on Fri Dec 15 15:40:26 GMT 2023
PRIMARY
INN
6027
Created by admin on Fri Dec 15 15:40:26 GMT 2023 , Edited by admin on Fri Dec 15 15:40:26 GMT 2023
PRIMARY
CHEBI
72564
Created by admin on Fri Dec 15 15:40:26 GMT 2023 , Edited by admin on Fri Dec 15 15:40:26 GMT 2023
PRIMARY
MERCK INDEX
m10552
Created by admin on Fri Dec 15 15:40:26 GMT 2023 , Edited by admin on Fri Dec 15 15:40:26 GMT 2023
PRIMARY Merck Index
WIKIPEDIA
TEMOZOLOMIDE
Created by admin on Fri Dec 15 15:40:26 GMT 2023 , Edited by admin on Fri Dec 15 15:40:26 GMT 2023
PRIMARY
PUBCHEM
5394
Created by admin on Fri Dec 15 15:40:26 GMT 2023 , Edited by admin on Fri Dec 15 15:40:26 GMT 2023
PRIMARY
DRUG BANK
DB00853
Created by admin on Fri Dec 15 15:40:26 GMT 2023 , Edited by admin on Fri Dec 15 15:40:26 GMT 2023
PRIMARY
SMS_ID
100000089638
Created by admin on Fri Dec 15 15:40:26 GMT 2023 , Edited by admin on Fri Dec 15 15:40:26 GMT 2023
PRIMARY
DAILYMED
YF1K15M17Y
Created by admin on Fri Dec 15 15:40:26 GMT 2023 , Edited by admin on Fri Dec 15 15:40:26 GMT 2023
PRIMARY
NSC
362856
Created by admin on Fri Dec 15 15:40:26 GMT 2023 , Edited by admin on Fri Dec 15 15:40:26 GMT 2023
PRIMARY
IUPHAR
7301
Created by admin on Fri Dec 15 15:40:26 GMT 2023 , Edited by admin on Fri Dec 15 15:40:26 GMT 2023
PRIMARY
NCI_THESAURUS
C1244
Created by admin on Fri Dec 15 15:40:26 GMT 2023 , Edited by admin on Fri Dec 15 15:40:26 GMT 2023
PRIMARY
Related Record Type Details
BASIS OF STRENGTH->SUBSTANCE
ASSAY (HPLC)
USP
Related Record Type Details
PRODRUG -> METABOLITE ACTIVE
METABOLITE -> PARENT
URINE
METABOLITE -> PARENT
Related Record Type Details
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
Related Record Type Details
ACTIVE MOIETY